Pelthos Therapeutics (PTHS) Non-Current Assets (2025 - 2026)
Pelthos Therapeutics (PTHS) posted quarterly Non-Current Assets of $77.0 million for Q4 2025, little changed quarter-over-quarter from $76.7 million in Q3 2025.
Pelthos Therapeutics (PTHS) Non-Current Assets (2025 - 2026) Analysis & Trends
Pelthos Therapeutics' Non-Current Assets history runs 1 years deep, the most recent figure standing at $77.0 million for Q4 2025.
- In Q4 2025, Non-Current Assets changed N/A year-over-year to $77.0 million; the TTM figure through Dec 2025 stood at $153.7 million (changed N/A YoY), while the FY2025 annual figure was $77.0 million, changed N/A from the prior year.
- Non-Current Assets for Q4 2025 stood at $77.0 million, roughly flat from $76.7 million in the prior quarter.
- The five-year high for Non-Current Assets was $77.0 million in Q4 2025, with the low at $76.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.76 Bn | 131.91 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 86.51 Bn | 78.51 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 65.74 Bn | 60.56 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 59.39 Bn | 54.26 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 42.24 Bn | 37.15 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.78 Bn | 28.47 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.65 Bn | 10.26 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.22 Bn | 26.39 Bn | - | 18.06 Bn |
| 10 | Pelthos Therapeutics | 93.05 Mn | 68.49 Mn | 21.23 Mn | 74.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 74.00 Mn |
| Dec 31, 2025 | 76.99 Mn |
| Sep 30, 2025 | 76.67 Mn |